Related Experiment Video
Updated: Jun 26, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Intensive insulin therapy in critical care settings
Darla Klug Eastman1, Michelle M Bottenberg, Karly A Hegge
1Veteran's Administration Central Iowa Healthcare System, Des Moines, IA 50310, USA. Darla.Eastman@drake.edu
Current Clinical Pharmacology
|January 20, 2009
Summary
Strict blood glucose control in hospitalized patients improves outcomes but poses risks like hypoglycemia. Hospitals are adopting protocols and interdisciplinary care to balance benefits and risks of intensive insulin therapy.
Area of Science:
- Critical care medicine
- Endocrinology
- Hospital administration
Background:
- Hyperglycemia in hospitalized patients increases morbidity and mortality, irrespective of diabetes status.
- Intravenous insulin therapy is often necessary in critical care to achieve glycemic goals.
- Intensive insulin therapy aims for blood glucose levels of 80–110 mg/dL, linked to improved outcomes.
Purpose of the Study:
- To evaluate the challenges and strategies for implementing intensive insulin therapy in hospitalized patients.
- To explore the balance between the benefits and risks of strict glycemic control.
Main Methods:
- Review of studies on intensive insulin therapy in critical care.
- Analysis of outcomes associated with maintaining specific blood glucose ranges.
- Examination of institutional approaches to glycemic control protocols.
Main Results:
- Strict glycemic control (80–110 mg/dL) can reduce mortality, infectious complications, hospital stay, and costs.
- Hypoglycemia is a significant risk associated with intensive insulin therapy, leading to study terminations.
- Close patient monitoring for insulin infusions increases ICU staff workload.
Conclusions:
- Balancing the benefits of intensive insulin therapy against the risks of hypoglycemia is crucial.
- Standardized protocols and interdisciplinary approaches are key to managing intensive insulin therapy effectively.
- Careful consideration of risks versus benefits is necessary for optimal patient outcomes.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:20Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
01:25Diabetic Ketoacidosis l: Introduction
DefinitionDiabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus, characterized by a triad of hyperglycemia (blood glucose >250 mg/dL), ketonemia or ketonuria, and metabolic acidosis (arterial pH <7.30 and serum bicarbonate <18 mEq/L). It results from insulin deficiency combined with elevated levels of counterregulatory hormones—glucagon, catecholamines, cortisol, and growth hormone—leading to increased lipolysis, hepatic ketone production, and...